MTOR and hepatocellular carcinoma: For in vitro and in silico experimental validation, we focused on the hepatocellular carcinoma (HCC) (i.e., a sub-type of liver cancer), which is the fourth most deadly cancer in the world [37], and on the PI3K/AKT/mTOR signalling pathway, due to its critical role in various types of cancer and cancer cell stemness [29].